CA2478931A1 - Methode de traitement du diabete sucre, y compris les etats associes au diabete sucre et les complications du diabete sucre - Google Patents

Methode de traitement du diabete sucre, y compris les etats associes au diabete sucre et les complications du diabete sucre Download PDF

Info

Publication number
CA2478931A1
CA2478931A1 CA002478931A CA2478931A CA2478931A1 CA 2478931 A1 CA2478931 A1 CA 2478931A1 CA 002478931 A CA002478931 A CA 002478931A CA 2478931 A CA2478931 A CA 2478931A CA 2478931 A1 CA2478931 A1 CA 2478931A1
Authority
CA
Canada
Prior art keywords
phytostanol
group
insulin
phytosterol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478931A
Other languages
English (en)
Inventor
Tatjana Lukic
Haydn P. Pritchard
Kishor M. Wasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of CA2478931A1 publication Critical patent/CA2478931A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement du diabète sucré et des états associés au diabète sucré chez un animal, consistant à administrer une quantité non toxique et thérapeutiquement efficace d'un ou de plusieurs des composés suivants, représentés par la formule (I, II, III) dans laquelle R est un fragment de phytostérol ou de phytostanol, R2 est un dérivé d'acide ascorbique et R3 est de l'hydrogène ou un métal, un métal terreux alcalin, ou un métal alcalin; et tous les sels de ceux-ci.
CA002478931A 2002-03-14 2003-03-14 Methode de traitement du diabete sucre, y compris les etats associes au diabete sucre et les complications du diabete sucre Abandoned CA2478931A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9874502A 2002-03-14 2002-03-14
US10/098,745 2002-03-14
PCT/CA2003/000369 WO2003075931A1 (fr) 2002-03-14 2003-03-14 Methode de traitement du diabete sucre, y compris les etats associes au diabete sucre et les complications du diabete sucre

Publications (1)

Publication Number Publication Date
CA2478931A1 true CA2478931A1 (fr) 2003-09-18

Family

ID=27804294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478931A Abandoned CA2478931A1 (fr) 2002-03-14 2003-03-14 Methode de traitement du diabete sucre, y compris les etats associes au diabete sucre et les complications du diabete sucre

Country Status (11)

Country Link
EP (1) EP1482950A1 (fr)
JP (1) JP2005528353A (fr)
KR (1) KR20040104513A (fr)
CN (1) CN1681514A (fr)
AU (1) AU2003218547B2 (fr)
BR (1) BR0308396A (fr)
CA (1) CA2478931A1 (fr)
NO (1) NO20044346L (fr)
NZ (1) NZ535200A (fr)
RU (1) RU2334518C2 (fr)
WO (1) WO2003075931A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
US7678399B2 (en) * 2005-12-05 2010-03-16 Bunge Oils, Inc. Phytosterol containing deep-fried foods and methods with health promoting characteristics
RU2547990C2 (ru) * 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CA2997231A1 (fr) * 2015-09-03 2017-03-09 Natural Shield Israel 2016 Ltd Compositions combinees pour reguler des niveaux de glycemie, l'hepatoprotection, et pour la prevention et le traitement d'etats medicaux associes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464465T3 (es) * 1994-09-29 2014-06-02 Pharmachem Laboratories, Inc. Composiciones de esteroles a partir de jabón de pulpa
EP1189924B1 (fr) * 1999-06-23 2004-08-18 Forbes Medi-Tech Inc. Conjugues de phytosterol ou de phytostanol et d'acide ascorbique, et leurs utilisations dans le traitement ou la prevention des maladies cardio-vasculaires

Also Published As

Publication number Publication date
NZ535200A (en) 2007-07-27
RU2004130463A (ru) 2005-04-10
CN1681514A (zh) 2005-10-12
RU2334518C2 (ru) 2008-09-27
BR0308396A (pt) 2005-01-11
NO20044346L (no) 2004-12-09
KR20040104513A (ko) 2004-12-10
JP2005528353A (ja) 2005-09-22
AU2003218547B2 (en) 2007-11-01
EP1482950A1 (fr) 2004-12-08
WO2003075931A1 (fr) 2003-09-18
AU2003218547A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
EP1227734B1 (fr) Compositions contenant des huiles ou des graisses comestibles ainsi que des phytost rols et/ou des phytostanols dissous
US20020156051A1 (en) Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
CN1436047A (zh) 促进血管健康的组合物和方法
CN1655806A (zh) 涉及缺损性间隙连接联系的疾病的治疗
CN101912090B (zh) 辅助降血脂青稞保健粥及其制备方法
Hu et al. Hydrophilic phytosterol derivatives: A short review on structural modifications, cholesterol-lowering activity and safety
US20030203854A1 (en) Composition for effecting serum cholesterol levels
AU2003218547B2 (en) A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
US9642875B2 (en) Compounds and their effects on appetite control and insulin sensitivity
WO2001066560A2 (fr) Nouveaux derives comprenant des phytosterols et/ou des phytostanols et des alpha-lipoiques et leur utilisation pour traiter ou prevenir les maladies cardio-vasculaires, leurs causes premieres et d'autres troubles
JP2008222656A (ja) 肥満改善および予防用組成物ならびに健康食品
EP1644007A1 (fr) Composition comprenant un ou plusieurs phytosterols et/ou phytostanols et glucomannan, et utilisations de cette composition dans le traitement des troubles lipidiques chez des individus souffrant ou non du diabete du type ii
KR100886466B1 (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
EP1333838B1 (fr) Composes comprenant du phytosterol et/ou du phytostanol et de l'acide ascorbique et leur utilisation comme agents de regulation du poids
WO2018124704A1 (fr) Composition favorisant l'excrétion de lipides végétaux et comprenant de l'allulose
ES2262655T3 (es) Nuevos compuestos cristalinos que comprenden fitosteroles y fitostanoles o sus derivados.
HK1075845A (en) A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
JP6770726B1 (ja) メタボリックシンドロームの予防または改善剤
AU2007203095A1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents
CA2461136A1 (fr) Procede de reduction du transfert in vivo d'esters de cholesteryl e dont la mediation est assuree par la proteine de transfert des esters de cholesterol, entre les lipoproteines de haute densite (hdl) et les lipoproteines de basse densite (ldl)
HK1055377B (en) Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein
KR20040017891A (ko) 레반을 이용한 비만 개선 식이 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued